MAP2 and Cerebral ischemia: Double immunofluorescence staining for NeuN/Caspase1, NeuN/GSDMD, NeuN/IL-1β, MAP2/ASC, MAP2/GSDMD and NLRP1/GSDMD further confirmed that iTBS post-treatment is capable of inhibiting cerebral ischemia-induced pyroptosis of neuron in peri-infarcted area rather than at the border of infarcted core.